NEW YORK, and CAMBRIDGE, Mass., April 7 /PRNewswire-FirstCall/ -- Javelin Pharmaceuticals, Inc. , a developer of innovative prescription pain medications, today announced that Daniel B. Carr, MD, Chief Executive Officer and Chief Medical Officer will be giving a plenary lecture entitled, Current and Investigational Strategies in Pain. The presentation will take place tonight, April 7, 2006, at 7:30 PM at The Marriott Marquis in Times Square.
“It’s a real honor being chosen by The American Conference on Pain Medicine to be plenary speaker,” said Daniel B. Carr, MD, Chief Executive Officer and Chief Medical Officer of Javelin Pharmaceuticals. “During my lecture, I will address recent advances in treating chronic, acute and breakthrough pain and will review newer investigational drug products, including two of Javelin’s late-state clinical candidates, Rylomine(TM) and PMI-150.”
Along with Dr. Carr, additional ACPM plenary faculty include:
Charles Argoff, MD, Jennifer Bolen, JD, Allan Basbaum, PhD, Daniel Brookoff, MD, Kathleen Foley, MD (keynote), Bill McCarberg, MD, Steve Passik, PhD, Russell Portenoy, MD, Srinivasa Raja, MD, Sanford H. Roth, MD, Gary Williams, MD, PhD.
About Javelin:
With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information, please visit the website at www.javelinpharmaceuticals.com.
ABOUT ACPM
The American Conference on Pain Medicine is a partnership between the Institute of Applied Science & Medicine and the world-renowned Johns Hopkins University School of Medicine. This meeting will disseminate clinically important information on the spectrum of chronic, acute and breakthrough pain, with educational tracks of particular clinical relevance for pain management specialists and primary care physicians. The unique two-track format will enable those attendees practicing primary care and those specializing in pain management to attend separate symposia tailored to each of their educational needs, while bringing all conference attendees together for joint plenary sessions covering topics with significant overlap across both healthcare fields.
Forward-looking Statement
Some of the statements included in this press release, particularly those anticipating future financial performance, clinical and business prospects for our lead drug candidates Dyloject(TM), Rylomine(TM) and PMI-150, growth and operating strategies and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete cost-effective clinical trials for the drug candidates in our pipelines, including Dyloject(TM), Rylomine(TM) and PMI-150; we may not be able to meet anticipated development timelines for Dyloject(TM), Rylomine(TM) and PMI-150 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.javelinpharmaceuticals.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.
Javelin Pharmaceuticals, Inc.
CONTACT: June Gregg of Javelin Pharmaceuticals, Inc., +1-212-554-4550,jgregg@javelinpharmaceuticals.com; or Bryan P. Murphy of LaVoie Group,+1-781-596-0200 ext. 105, bmurphy@lavoiegroup.com
Web site: http://www.javelinpharmaceuticals.com/
